Compass Pathways plc
Pioneering psychedelic mental health
London, UK
Compass Pathways plc is a biotechnology company focused on accelerating patient access to evidence-based innovation in mental health, pioneering COMP360, an investigational synthetic psilocybin treatment for people with serious mental health conditions, particularly treatment-resistant depression (TRD).
How We Help
Problem Statement
Addressing serious mental health conditions with high unmet needs and limitations of conventional treatments, Compass Pathways aims to provide rapid and durable responses through novel psychedelic-assisted therapies.
Core Technology
COMP360, an investigational synthetic psilocybin treatment
Key Differentiators
Pioneering a new model of psilocybin therapy integrating its proprietary COMP360 formulation with psychological support; holding FDA Breakthrough Therapy designation and UK Innovative Licensing and Access Pathway (ILAP) designation for TRD; conducting the largest-to-date randomized, controlled, double-blind psilocybin treatment clinical program; emphasizing rapid and durable responses; holding key patents covering COMP360 crystalline psilocybin polymorph A; and a strong commitment to scientific rigor, integrity, and collaboration.
Clinical Focus
Primarily serious mental health conditions with high unmet needs, including Treatment-Resistant Depression (TRD), Post-Traumatic Stress Disorder (PTSD), Anorexia Nervosa, Major Depressive Disorder (MDD), chronic cluster headache, body dysmorphic disorder, suicidal ideation, and autism.
Target Customers
Certified third-party treatment centers
Company Info
- Business Model
- Pre-commercial stage biotechnology company focused on funding the research and development of its lead drug candidate, COMP360. The future strategy involves commercial sale of its proprietary, single-administration therapy (delivered with psychological support) to certified third-party treatment centers, generating revenue from drug price, session frequency, and payer reimbursement for therapist and clinic services.
- Founded
- 2016
- Total Funding
- 744,000,000
- Website
- compasspathways.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
COMP360 has successfully completed two pivotal Phase 3 trials (COMP005 & COMP006) for TRD, both meeting primary endpoints with statistically significant and clinically meaningful reductions in depression symptoms. It holds FDA Breakthrough Therapy designation and UK ILAP designation for TRD. A Phase 2b/3 trial for PTSD has been initiated following positive Phase 2 open-label study results, showing safety and rapid, durable improvement.
IP Protection
Holds key patents covering its COMP360 crystalline psilocybin polymorph A.
MedStartr Index Score
?What do you think of Compass Pathways plc?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.